Prognostic Significance of Tumor Regression Rate during Concurrent Chemoradiotherapy in Locally Advanced Cervix Cancer: Analysis by Radiation Phase and Histologic Type
Abstract
:1. Introduction
2. Materials and Methods
2.1. Inclusion and Exclusion Criteria
2.2. Treatment
2.3. Assessment of Treatment Outcomes
2.4. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Conflicts of Interest
References
- Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2019. CA Cancer J. Clin. 2019, 69, 7–34. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rose, P.G.; Java, J.J.; Whitney, C.W.; Stehman, F.B.; Lanciano, R.; Thomas, G.M. Locally advanced adenocarcinoma and adenosquamous carcinomas of the cervix compared to squamous cell carcinomas of the cervix in gynecologic oncology group trials of cisplatin-based chemoradiation. Gynecol. Oncol. 2014, 135, 208–212. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rose, P.G.; Bundy, B.N.; Watkins, E.B.; Thigpen, J.T.; Deppe, G.; Maiman, M.A.; Clarke-Pearson, D.L.; Insalaco, S. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N. Engl. J. Med. 1999, 340, 1144–1153. [Google Scholar] [CrossRef]
- Keys, H.M.; Bundy, B.N.; Stehman, F.B.; Muderspach, L.I.; Chafe, W.E.; Suggs, C.L., III; Walker, J.L.; Gersell, D. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N. Engl. J. Med. 1999, 340, 1154–1161. [Google Scholar] [CrossRef]
- Cho, O.; Chun, M. Management for locally advanced cervical cancer: New trends and controversial issues. Radiat. Oncol. J. 2018, 36, 254–264. [Google Scholar] [CrossRef] [Green Version]
- Banerjee, R.; Kamrava, M. Brachytherapy in the treatment of cervical cancer: A review. Int. J. Womens Health 2014, 6, 555–564. [Google Scholar]
- Logsdon, M.D.; Eifel, P.J. Figo IIIB squamous cell carcinoma of the cervix: An analysis of prognostic factors emphasizing the balance between external beam and intracavitary radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 1999, 43, 763–775. [Google Scholar] [CrossRef]
- Hardt, N.; van Nagell, J.R.; Hanson, M.; Donaldson, E.; Yoneda, J.; Maruyama, Y. Radiation-induced tumor regression as a prognostic factor in patients with invasive cervical cancer. Cancer 1982, 49, 35–39. [Google Scholar] [CrossRef]
- Nam, H.; Park, W.; Huh, S.J.; Bae, D.S.; Kim, B.G.; Lee, J.H.; Lee, J.W.; Lim, D.H.; Han, Y.; Park, H.C.; et al. The prognostic significance of tumor volume regression during radiotherapy and concurrent chemoradiotherapy for cervical cancer using MRI. Gynecol. Oncol. 2007, 107, 320–325. [Google Scholar] [CrossRef]
- Grossman, I.; Kurohara, S.S.; Webster, J.H.; George, F.W., III. The prognostic significance of tumor response during radiotherapy in cervical carcinoma. Radiology 1973, 107, 411–415. [Google Scholar] [CrossRef]
- Wang, J.Z.; Mayr, N.A.; Zhang, D.; Li, K.; Grecula, J.C.; Montebello, J.F.; Lo, S.S.; Yuh, W.T. Sequential magnetic resonance imaging of cervical cancer: The predictive value of absolute tumor volume and regression ratio measured before, during, and after radiation therapy. Cancer 2010, 116, 5093–5101. [Google Scholar]
- Yalman, D.; Aras, A.B.; Ozkok, S.; Duransoy, A.; Celik, O.K.; Ozsaran, Z.; Haydaroglu, A. Prognostic factors in definitive radiotherapy of uterine cervical cancer. Eur. J. Gynaecol. Oncol. 2003, 24, 309–314. [Google Scholar]
- Fyles, A.W.; Pintilie, M.; Kirkbride, P.; Levin, W.; Manchul, L.A.; Rawlings, G.A. Prognostic factors in patients with cervix cancer treated by radiation therapy: Results of a multiple regression analysis. Radiother. Oncol. 1995, 35, 107–117. [Google Scholar]
- Mayr, N.A.; Taoka, T.; Yuh, W.T.; Denning, L.M.; Zhen, W.K.; Paulino, A.C.; Gaston, R.C.; Sorosky, J.I.; Meeks, S.L.; Walker, J.L.; et al. Method and timing of tumor volume measurement for outcome prediction in cervical cancer using magnetic resonance imaging. Int. J. Radiat. Oncol. Biol. Phys. 2002, 52, 14–22. [Google Scholar]
- Minkoff, D.; Gill, B.S.; Kang, J.; Beriwal, S. Cervical cancer outcome prediction to high-dose rate brachytherapy using quantitative magnetic resonance imaging analysis of tumor response to external beam radiotherapy. Radiother. Oncol. 2015, 115, 78–83. [Google Scholar]
- Couvreur, K.; Naert, E.; De Jaeghere, E.; Tummers, P.; Makar, A.; De Visschere, P.; Van Bockstal, M.; Van Dorpe, J.; De Neve, W.; Denys, H.; et al. Neo-adjuvant treatment of adenocarcinoma and squamous cell carcinoma of the cervix results in significantly different pathological complete response rates. BMC Cancer 2018, 18, 1101. [Google Scholar]
- Poujade, O.; Morice, P.; Rouzier, R.; Madelenat, P.; Lecuru, F.; Muray, J.M.; Mathevet, P.; Alran, S.; Salmon, R.J.; Reyal, F. Pathologic response rate after concomitant neo-adjuvant radiotherapy and chemotherapy for adenocarcinoma of the uterine cervix: A retrospective multicentric study. Int. J. Gynecol. Cancer 2010, 20, 815–820. [Google Scholar]
- Oh, D.; Lee, J.E.; Huh, S.J.; Park, W.; Nam, H.; Choi, J.Y.; Kim, B.-T. Prognostic significanceof tumor response as assessed by sequential 18F-fluorodeoxyglucose-positron emission tomography/computed tomography during concurrent chemoradiation therapy for cervical cancer. Int. J. Radiat. Oncol. Biol. Phys. 2013, 87, 549–554. [Google Scholar]
- Oh, D.; Huh, S.J.; Park, W.; Ju, S.G.; Nam, H.; Lee, J.E. Clinical outcomes in cervical cancer patients treated by FDG-PET/CT-based 3-dimensional planning for the first brachytherapy session. Medicine 2016, 95, e3895. [Google Scholar]
- Katanyoo, K.; Sanguanrungsirikul, S.; Manusirivithaya, S. Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma in locally advanced cervical cancer. Gynecol. Oncol. 2012, 125, 292–296. [Google Scholar]
- Galic, V.; Herzog, T.J.; Lewin, S.N.; Neugut, A.I.; Burke, W.M.; Lu, Y.S.; Hershman, D.L.; Wright, J.D. Prognostic significance of adenocarcinoma histology in women with cervical cancer. Gynecol. Oncol. 2012, 125, 287–291. [Google Scholar] [CrossRef] [PubMed]
- Yokoi, E.; Mabuchi, S.; Takahashi, R.; Matsumoto, Y.; Kuroda, H.; Kozasa, K.; Kimura, T. Impact of histological subtype on survival in patients with locally advanced cervical cancer that were treated with definitive radiotherapy: Adenocarcinoma/adenosquamous carcinoma versus squamous cell carcinoma. J. Gynecol. Oncol. 2017, 28, e19. [Google Scholar] [CrossRef] [Green Version]
- Chen, J.L.; Huang, C.Y.; Huang, Y.S.; Chen, R.J.; Wang, C.W.; Chen, Y.H.; Cheng, J.C.; Cheng, A.L.; Kuo, S.H. Differential clinical characteristics, treatment response and prognosis of locally advanced adenocarcinoma/adenosquamous carcinoma and squamous cell carcinoma of cervix treated with definitive radiotherapy. Acta Obstet. Gynecol. Scand. 2014, 93, 661–668. [Google Scholar] [CrossRef] [PubMed]
- Oka, K.; Nakano, T.; Hoshi, T. Analysis of response to radiation therapy of patients with cervical adenocarcinoma compared with squamous cell carcinoma. MIB-1 and PC10 labeling indices. Cancer 1996, 77, 2280–2285. [Google Scholar] [CrossRef]
- Nakamura, E.; Iwakawa, M.; Furuta, R.; Ohno, T.; Satoh, T.; Nakawatari, M.; Ishikawa, K.; Imadome, K.; Michikawa, Y.; Tamaki, T.; et al. Villin1, a novel diagnostic marker for cervical adenocarcinoma. Cancer Biol. Ther. 2009, 8, 1146–1153. [Google Scholar] [CrossRef] [Green Version]
- Kim, Y.B.; Kim, G.E.; Pyo, H.R.; Cho, N.H.; Keum, K.C.; Lee, C.G.; Seong, J.; Suh, C.O.; Park, T.K. Differential cyclooxygenase-2 expression in squamous cell carcinoma and adenocarcinoma of the uterine cervix. Int. J. Radiat. Oncol. Biol. Phys. 2004, 60, 822–829. [Google Scholar] [CrossRef]
- Moyses, H.M.; Morrow, C.P.; Muderspach, L.I.; Roman, L.D.; Vasilev, S.A.; Petrovich, Z.; Groshen, S.L.; Klement, V. Residual disease in the uterus after preoperative radiotherapy and hysterectomy in stage IB cervical carcinoma. Am. J. Clin. Oncol. 1996, 19, 433–438. [Google Scholar] [CrossRef]
- Tang, J.; Tang, Y.; Yang, J.; Huang, S. Chemoradiation and adjuvant chemotherapy in advanced cervical adenocarcinoma. Gynecol. Oncol. 2012, 125, 297–302. [Google Scholar] [CrossRef]
- Yang, J.; Yang, J.; Cao, D.; Shen, K.; Ma, J.; Zhang, F. Completion hysterectomy after chemoradiotherapy for locally advanced adeno-type cervical carcinoma: Updated survival outcomes and experience in post radiation surgery. J. Gynecol. Oncol. 2020, 31, e16. [Google Scholar] [CrossRef]
- Hatano, K.; Sekiya, Y.; Araki, H.; Sakai, M.; Togawa, T.; Narita, Y.; Akiyama, Y.; Kimura, S.; Ito, H. Evaluation of the therapeutic effect of radiotherapy on cervical cancer using magnetic resonance imaging. Int. J. Radiat. Oncol. Biol. Phys. 1999, 45, 639–644. [Google Scholar] [CrossRef]
- National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Cervical Cancer (Version 4.2019—29 March 2019). Available online: https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf (accessed on 1 July 2020).
- Toita, T.; Kodaira, T.; Shinoda, A.; Uno, T.; Akino, Y.; Mitsumori, M.; Teshima, T. Patterns of radiotherapy practice for patients with cervical cancer (1999–2001): Patterns of care study in Japan. Int. J. Radiat. Oncol. Biol. Phys. 2008, 70, 788–794. [Google Scholar] [CrossRef] [PubMed]
- Viswanathan, A.N.; Creutzberg, C.L.; Craighead, P.; McCormack, M.; Toita, T.; Narayan, K.; Reed, N.; Long, H.; Kim, H.-J.; Marth, C.; et al. International brachytherapy practice patterns: A survey of the gynecologic cancer intergroup (GCIG). Int. J. Radiat. Oncol. Biol. Phys. 2012, 82, 250–255. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Toita, T.; Kitagawa, R.; Hamano, T.; Umayahara, K.; Hirashima, Y.; Aoki, Y.; Oguchi, M.; Mikami, M.; Takizawa, K. Phase II study of concurrent chemoradiotherapy with high-dose-rate intracavitary brachytherapy in patients with locally advanced uterine cervical cancer: Efficacy and toxicity of a low cumulative radiation dose schedule. Gynecol. Oncol. 2012, 126, 211–216. [Google Scholar] [CrossRef]
- Tanderup, K.; Fokdal, L.U.; Sturdza, A.; Haie-Meder, C.; Mazeron, R.; van Limbergen, E.; Jürgenliemk-Schulz, I.; Petric, P.; Hoskin, P.; Dörr, W.; et al. Effect of tumor dose, volume and overall treatment time on local control after radiochemotherapy including MRI guided brachytherapy of locally advanced cervical cancer. Radiother. Oncol. 2016, 120, 441–446. [Google Scholar] [CrossRef]
Characteristics | Number of Patients (%) | ||||
---|---|---|---|---|---|
. | All Patients (n = 398) | SCC (n = 354) | AC/SCC (n = 44) | p-Value | |
Age (years) | Mean ± SD | 57.1 ± 11.9 | 57.4 ± 12.0 | 56.5 ± 12.2 | 0.615 |
≤50 | 111 (27.9) | 97 (27.4) | 14 (31.8) | 0.538 | |
>50 | 287 (72.1) | 257 (72.6) | 30 (68.2) | ||
Pretreatment Hb (g/dL) | Mean ± SD | 11.5 ± 1.9 | 11.5 ± 1.8 | 11.9 ± 2.1 | 0.146 |
<11 | 126 (31.6) | 113 (31.9) | 13 (29.5) | 0.749 | |
≥11 | 272 (68.4) | 241 (68.1) | 31 (70.5) | ||
FIGO stage | IIB | 232 (58.3) | 206 (58.2) | 26 (59.1) | 0.877 |
IIIA | 19 (4.8) | 16 (4.5) | 3 (6.8) | ||
IIIB | 84 (21.1) | 75 (21.2) | 9 (20.5) | ||
IIIC | 20 (5.0) | 19 (5.4) | 1 (2.3) | ||
IVA | 43 (10.8) | 38 (10.7) | 5 (11.4) | ||
Tumor marker | SCC (ng/mL) | 21.9 ± 38.9 | 23.2 ± 39.1 | 11.4 ± 36.3 | 0.295 |
CEA (ng/mL) | 12.8 ± 131.8 | 14.1 ± 140.7 | 4.3 ± 7.4 | 0.534 | |
CA-125 (U/mL) | 65.2 ± 201.5 | 63.1 ± 227.8 | 70.4 ± 116 | 0.650 | |
LN metastasis | Negative | 282 (70.9) | 250 (70.6) | 32 (72.7) | 0.772 |
Positive | 116 (29.1) | 104 (29.4) | 12 (27.3) | ||
Tumor size (cm) | Mean ± SD | 5.3 ± 1.9 | 5.4 ± 1.8 | 5.4 ± 2.3 | 0.888 |
≤4.0 | 97 (24.4) | 84 (23.7) | 13 (29.5) | 0.397 | |
>4.0 | 301 (75.6) | 270 (76.3) | 31 (70.5) | ||
Duration of RT (days) | Median (IQR) | 54 (49–60) | 54 (49–60) | 53 (49–58) | 0.350 |
RT Response | SCC | AC/ASC | p-Value |
---|---|---|---|
Post-EBRT response | |||
EBRTregression (%) | 53.6% ± 26.1 | 32.8% ± 29.9 | <0.001 |
CR | 48 (13.6) | 3 (6.8) | <0.001 |
PR | 245 (69.2) | 18 (40.9) | |
SD | 61 (17.2) | 23 (52.3) | |
PD | 0 | 0 | |
Post-ICR response | |||
ICRregression (%) | 73.6% ± 31.3 | 77.9% ± 22.7 | 0.400 |
CR | 163 (53.3) | 19 (46.3) | 0.683 |
PR | 107 (35.0) | 17 (41.5) | |
SD | 36 (10.2) | 5 (12.2) | |
PD | 0 | 0 | |
Post-RT response | |||
RTregression (%) | 87.0% ± 19.3 | 83.2% ± 22.3 | 0.222 |
CR | 211 (59.6) | 22 (50.0) | 0.474 |
PR | 136 (38.4) | 21 (47.7) | |
SD | 7 (2.0) | 1 (2.3) | |
PD | 0 | 0 | |
EBRTproportion (%) | 60.5% (43.1–79.5) | 30.9% (13.7–56.6) | <0.001 |
Good EBRT responders (EBRTregression > 26%) | 303 (85.6) | 23 (52.3) | <0.001 |
Poor EBRT responders (EBRTregression ≤ 26%) | 51 (14.4) | 21 (47.7) | |
More EBRT responders (EBRTproportion > 40%) | 277 (78.2) | 17 (38.6) | <0.001 |
More ICR responders (EBRTproportion ≤ 40%) | 77 (21.8) | 27 (61.4) | |
Good RT responders (RTregression > 92%) | 212 (50.9) | 24 (54.5) | 0.518 |
Poor RT responders (RTregression ≤ 92%) | 142 (40.1) | 20 (45.5) |
Characteristics | PFS | OS | ||
---|---|---|---|---|
Hazard Ratio (95%, CI) | p-Value | Hazard Ratio (95%, CI) | p-Value | |
Cell type | ||||
SCC | 1 | 1 | ||
AC/ASC | 2.37 (1.45–3.89) | 0.001 | 1.91 (1.18–3.09) | 0.009 |
Pretreatment Hb | ||||
<11 (g/dL) | 1 | 1 | ||
≥11 (g/dL) | 1.07 (0.71–1.64) | 0.727 | 0.92 (0.62–1.35) | 0.687 |
Stage | ||||
II | 1 | |||
III | 1.52 (0.99–2.33) | 0.056 | 1.91 (1.19–3.05) | 0.007 |
IV | 1.47 (0.79–2.73) | 0.219 | 2.08 (1.05–4.12) | 0.035 |
LN metastasis | ||||
Negative | 1 | 1 | ||
Positive | 1.12 (0.75–1.66) | 0.890 | 1.05 (0.67–1.32) | 0.253 |
Tumor size | ||||
≤4.0 cm | 1 | 1 | ||
>4.0 cm | 1.64 (1.01–2.67) | 0.044 | 1.52 (0.95–2.42) | 0.037 |
EBRT regression | ||||
>26% | 1 | 1 | ||
≤26% | 2.16 (1.38–3.37) | 0.001 | 2.53 (1.54–3.67) | 0.008 |
EBRT proportion | ||||
>40% | 1 | 1 | ||
≤40% | 2.43 (1.12–2.56) | 0.031 | 2.59 (1.15–2.74) | 0.015 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kang, J.-H.; Cho, W.K.; Yeo, H.J.; Jeong, S.Y.; Noh, J.J.; Shim, J.I.; Lee, Y.-Y.; Kim, T.-J.; Lee, J.-W.; Kim, B.-G.; et al. Prognostic Significance of Tumor Regression Rate during Concurrent Chemoradiotherapy in Locally Advanced Cervix Cancer: Analysis by Radiation Phase and Histologic Type. J. Clin. Med. 2020, 9, 3471. https://doi.org/10.3390/jcm9113471
Kang J-H, Cho WK, Yeo HJ, Jeong SY, Noh JJ, Shim JI, Lee Y-Y, Kim T-J, Lee J-W, Kim B-G, et al. Prognostic Significance of Tumor Regression Rate during Concurrent Chemoradiotherapy in Locally Advanced Cervix Cancer: Analysis by Radiation Phase and Histologic Type. Journal of Clinical Medicine. 2020; 9(11):3471. https://doi.org/10.3390/jcm9113471
Chicago/Turabian StyleKang, Jun-Hyeok, Won Kyung Cho, Hie Jun Yeo, Soo Young Jeong, Joseph J. Noh, Jung In Shim, Yoo-Young Lee, Tae-Joong Kim, Jeong-Won Lee, Byoung-Gie Kim, and et al. 2020. "Prognostic Significance of Tumor Regression Rate during Concurrent Chemoradiotherapy in Locally Advanced Cervix Cancer: Analysis by Radiation Phase and Histologic Type" Journal of Clinical Medicine 9, no. 11: 3471. https://doi.org/10.3390/jcm9113471